

INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTY. DOCKET NO. 44033-093		SERIAL NO. 09/544,984	RECEIV
Q ST				PPLICANT UEC 07 200			
(PTO-1449)		(449)	ING DATE OF PRINCIPLE OF PRINCI		0	GROUP 1614	TECH CENTER 1600/2
		U.S	S. PATRICE	DOCUMENT	rs .		
EXAMINER'S INITIALS			1	IAME	CLASS	SUBCLASS	FILING DATE
			IGNPATE	NT DOCUME	ENTS		
EXAMINER'S INITIALS	ER'S			UNTRY	CLASS	SUBCLASS	Translation Yes No
		·					
	"Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Required for In Vitro Generation of IL-4-producing Cells", by Le Gros, et al., The Journal of Experimental Medicine, Vol. 172, Septembre 1990, pp. 921-929. "Inhibition of Human Interleukin-12 Production by Pentoxifylline", by Moller et al., Immunology, Vol. 91, 1997, pp. 197-203. "The Immunology of Mutliple Sclerosis and its Animal Model, Experimental Allergic Encephalomyelitis", by Owens et al., Neurologic Clinics, Vol. 13, No. 1, February 1995. "Interleukin 12", R& D Systems Catalog, pp. 67-69, 1995. "Long-term Treatment of Chronic Relapsing Experimental Allergic Encephalomyelitis by Transforming Growth Factor-β2", by Racke et al., Journal of Neuroimmunology, Vol. 46, 1993, pp. 175-184. "Phosphodiesterase Inhibitor Pentoxifylline, a Selective Suppressor of T Helper Type 1- but not Type 2-associated Lymphokine Production, Prevents Induction of Experimental Autoimmune Encephalomyelitis in Lewis Rats", by Rott et al., Eur. J. Immumol., Vol. 23, 1993, pp. 1745- 1751. "The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases", by Trembleau et al., Immunology Today, Vol. 16, No. 8, 1995, pp. 383-386. Remington Pharmaceutical Sciences, Chapters 83-92, 1990, pp. 1519-1751.						
1	rollington i narmaceutear belences, Chapters 65-72, 1770, pp. 1317-1731.						
EXAMINER	hi.	as	D	ATE CONSID		W	